Ionis Pharmaceuticals
IONS
330 hedge funds and large institutions have $6.37B invested in Ionis Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 51 funds opening new positions, 90 increasing their positions, 116 reducing their positions, and 43 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 6 → 9 (+3)
19% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 43
2% more funds holding
Funds holding: 322 → 330 (+8)
4% more capital invested
Capital invested by funds: $6.11B → $6.37B (+$260M)
0.68% less ownership
Funds ownership: 86.27% → 85.59% (-0.68%)
22% less repeat investments, than reductions
Existing positions increased: 90 | Existing positions reduced: 116
43% less call options, than puts
Call options by funds: $64.2M | Put options by funds: $112M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$37.6M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
+$33.3M |
| 3 |
Morgan Stanley
New York
|
+$24.3M |
| 4 |
American Century Companies
Kansas City,
Missouri
|
+$21.1M |
| 5 |
Two Sigma Advisers
New York
|
+$15.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$85.1M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$26M |
| 3 |
Fiera Capital (Canada)
Montreal,
Quebec, Canada
|
-$25.4M |
| 4 |
State Street
Boston,
Massachusetts
|
-$24.5M |
| 5 |
Goldman Sachs
New York
|
-$20.9M |
IONS Hedge Fund Activity: Q4 2018 in Review
330 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Ionis Pharmaceuticals (IONS) for Q4 2018, worth a combined $6.37B — up 4.3% from $6.11B a quarter earlier.
Buyers outnumbered sellers: 51 funds opened new IONS positions and 43 closed out — a net gain of 8 holders — while 90 added to existing stakes and 116 trimmed.
The largest buyer was Vanguard Group, adding an estimated $37.6M. The largest seller was Wellington Management Group, cutting an estimated $85.1M.
- 330 institutional investors held Ionis Pharmaceuticals (IONS) as of Q4 2018, up from 322 in Q3 2018.
- Funds reported $6.37B of Ionis Pharmaceuticals stock for Q4 2018, up 4.3% quarter-over-quarter.
- 51 funds opened new Ionis Pharmaceuticals positions in Q4 2018 and 43 closed out, a net change of +8 holders.
- The largest Ionis Pharmaceuticals buyer in Q4 2018 was Vanguard Group, an estimated $37.6M added.
- The largest Ionis Pharmaceuticals seller in Q4 2018 was Wellington Management Group, an estimated $85.1M sold.
Based on aggregated 13F filings for Q4 2018.